A detailed history of Legal & General Group PLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 65,544 shares of DYN stock, worth $2.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,544
Previous 44,101 48.62%
Holding current value
$2.22 Million
Previous $1.25 Million 84.74%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$23.65 - $35.63 $507,126 - $764,014
21,443 Added 48.62%
65,544 $2.31 Million
Q1 2024

May 14, 2024

BUY
$13.06 - $29.18 $258,940 - $578,551
19,827 Added 81.68%
44,101 $1.25 Million
Q4 2023

Feb 15, 2024

BUY
$6.62 - $13.64 $1,204 - $2,482
182 Added 0.76%
24,274 $322,000
Q3 2023

Nov 14, 2023

SELL
$8.6 - $12.18 $3,508 - $4,969
-408 Reduced 1.67%
24,092 $215,000
Q2 2023

Aug 14, 2023

BUY
$8.53 - $14.28 $117,679 - $197,006
13,796 Added 128.89%
24,500 $275,000
Q1 2023

May 15, 2023

BUY
$10.88 - $15.0 $3,068 - $4,230
282 Added 2.71%
10,704 $123,000
Q3 2022

Nov 14, 2022

SELL
$7.2 - $15.17 $16,812 - $35,421
-2,335 Reduced 18.3%
10,422 $133,000
Q2 2022

Aug 22, 2022

BUY
$4.36 - $10.5 $20,836 - $50,179
4,779 Added 59.9%
12,757 $88,000
Q3 2021

Nov 15, 2021

BUY
$15.6 - $21.46 $71,401 - $98,222
4,577 Added 134.58%
7,978 $129,000
Q2 2021

Aug 12, 2021

BUY
$15.94 - $22.33 $26,858 - $37,626
1,685 Added 98.19%
3,401 $71,000
Q1 2021

May 17, 2021

BUY
$14.0 - $29.3 $3,346 - $7,002
239 Added 16.18%
1,716 $27,000
Q4 2020

Feb 12, 2021

BUY
$16.81 - $23.94 $16,507 - $23,509
982 Added 198.38%
1,477 $31,000
Q3 2020

Nov 13, 2020

BUY
$20.0 - $23.9 $9,900 - $11,830
495 New
495 $10,000

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.75B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.